Quick Links
Resources
About myHIVteam
Powered By
In a groundbreaking move, the U.S. Food and Drug Administration (FDA) approved the first-ever gene editing therapy for sickle cell disease in December 2023. Although a significant step forward, challenges such as the exorbitant cost, limited administration centers, and intensive medical care hinder its widespread use, especially in regions like Africa where the need is critical. Despite these hurdles, the therapy marks a crucial advancement, utilizing CRISPR, the Nobel Prize-winning gene… read more
I read that the EBT-101 study has so far only tested 3 male patients. The patients did not experience adverse effects from the therapy. We are still waiting for data on what happens to the patients’ viral load when they stop taking their HIV meds. The study will also follow them up for 15 years to see if they get undesirable effects such as cancer, from the therapy having deleted genetic material not relating to the virus.
The study will look at 9 patients in total in groups of 3. The next group of 3 will receive a higher dose of EBT-101. The final group will get a higher dose again.
It will be really interesting to see what data comes next.
A long way to success, but the science is sound. Maybe AI can help us work through the problems(?). No longer science fiction. Thanks @A myHIVteam Member
I thought it was interesting that they wanted to see if EBT-101 could be passed on to a partner in the process of sex. Could it wind up upsetting reproduction in a female or fetus(?). It was not present in seminal fluids.
I got the impression from the last article I read that EBT-101 had not yet been tested(?). They were at the place of testing the carrier bacteriophages. Maybe there has been progress since that article was written(?)
Continue with Facebook
Sign up with your email
Your privacy is our priority. By continuing, you accept our
Terms of use, and our
Health Data and
Privacy policies.
A myHIVte...
